|
KR101958753B1
(ko)
|
2010-04-13 |
2019-03-15 |
셀덱스 쎄라퓨틱스, 인크. |
인간 ｃｄ27에 결합하는 항체 및 이의 용도
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
WO2014066532A1
(en)
|
2012-10-23 |
2014-05-01 |
Bristol-Myers Squibb Company |
Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
|
|
EP4223770A3
(en)
|
2012-11-05 |
2023-10-18 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
EP3939614A1
(en)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
US10081681B2
(en)
|
2013-09-20 |
2018-09-25 |
Bristol-Myers Squibb Company |
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
|
|
PE20160953A1
(es)
|
2013-12-12 |
2016-09-26 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
WO2016019232A1
(en)
|
2014-08-01 |
2016-02-04 |
John Vasilakos |
Methods and therapeutic combinations for treating tumors
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
US10688171B2
(en)
|
2015-02-10 |
2020-06-23 |
Ohio State Innovation Foundation |
Chlamydia-activated B cell platforms and methods thereof
|
|
EP3268037B1
(en)
*
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
BR112017020002A2
(en)
|
2015-03-20 |
2018-06-19 |
Syndax Pharmaceuticals, Inc. |
COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
WO2016168133A1
(en)
*
|
2015-04-17 |
2016-10-20 |
Merck Sharp & Dohme Corp. |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
|
DE112016002056T5
(de)
|
2015-05-06 |
2018-02-08 |
Snipr Technologies Limited |
Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
MX2017015308A
(es)
|
2015-05-29 |
2018-07-06 |
Merck Sharp & Dohme |
Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.
|
|
CA2986705A1
(en)
*
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
|
|
US10894044B2
(en)
|
2015-09-16 |
2021-01-19 |
Board Of Regents, The University Of Texas System |
Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
|
|
US11639389B2
(en)
*
|
2015-09-30 |
2023-05-02 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
|
US10149887B2
(en)
*
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
|
CN108430492B
(zh)
*
|
2015-10-23 |
2022-05-03 |
阿珀吉科吉尼科斯股份公司 |
单链cd27受体激动剂蛋白
|
|
TWI805542B
(zh)
*
|
2015-10-23 |
2023-06-21 |
日商坎巴斯有限公司 |
用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合
|
|
WO2017079202A1
(en)
|
2015-11-02 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Methods of cd40 activation and immune checkpoint blockade
|
|
US10744134B2
(en)
|
2015-11-04 |
2020-08-18 |
Astellas Pharma Inc. |
Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient
|
|
CN108884159A
(zh)
|
2015-11-07 |
2018-11-23 |
茂体外尔公司 |
用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
|
|
US10835601B2
(en)
|
2015-11-10 |
2020-11-17 |
Ohio State Innovation Foundation |
Methods and compositions related to accelerated humoral affinity
|
|
MX2018007406A
(es)
|
2015-12-16 |
2018-08-15 |
Merck Sharp & Dohme |
Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
|
|
CN108601731A
(zh)
|
2015-12-16 |
2018-09-28 |
磨石肿瘤生物技术公司 |
新抗原的鉴别、制造及使用
|
|
SI3394103T1
(sl)
|
2015-12-22 |
2023-10-30 |
Regeneron Pharmaceuticals, Inc. |
Kombinacija protiteles proti-PD-1 in bispecifičnih protiteles proti-CD20/proti-CD3 za zdravljenje raka
|
|
WO2017123643A1
(en)
*
|
2016-01-11 |
2017-07-20 |
Flagship Pioneering, Inc. |
Methods and compositions for modulating thymic function
|
|
EP3419645B1
(en)
|
2016-02-23 |
2020-09-02 |
BioLineRx Ltd. |
Method of selecting a treatment regimen in acute myeloid leukemia (aml)
|
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
|
EP3445783A2
(en)
|
2016-04-18 |
2019-02-27 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
CA3022377A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
|
TW202408578A
(zh)
|
2016-05-13 |
2024-03-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
MA45123A
(fr)
|
2016-05-27 |
2019-04-10 |
Agenus Inc |
Anticorps anti-tim-3 et leurs méthodes d'utilisation
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
|
JP7146732B2
(ja)
|
2016-07-13 |
2022-10-04 |
オハイオ ステート イノベーション ファウンデーション |
宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
|
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
EP3518946A4
(en)
|
2016-09-27 |
2020-09-09 |
Board of Regents, The University of Texas System |
METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
|
|
CA3037380A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
|
JP7041136B2
(ja)
|
2016-10-12 |
2022-03-23 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｔｕｓｃ２免疫療法のための方法および組成物
|
|
EP3538112A4
(en)
|
2016-11-09 |
2020-09-02 |
Musc Foundation for Research Development |
CD38-NAD + REGULATED METABOLIC AXIS IN ANTITUMOR IMMUNOTHERAPY
|
|
MA46852A
(fr)
|
2016-11-17 |
2019-09-25 |
Univ Texas |
Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
|
|
WO2018106729A1
(en)
*
|
2016-12-05 |
2018-06-14 |
G1 Therapeutics, Inc. |
Preservation of immune response during chemotherapy regimens
|
|
FI3551660T3
(fi)
|
2016-12-07 |
2023-12-11 |
Agenus Inc |
Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
|
|
EP3551226A1
(en)
|
2016-12-12 |
2019-10-16 |
MultiVir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
CA3054571A1
(en)
|
2017-02-24 |
2018-08-30 |
Board Of Regents,The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
KR20240042244A
(ko)
|
2017-05-19 |
2024-04-01 |
신닥스 파마슈티컬스, 인크. |
조합 요법
|
|
HUE065242T2
(hu)
|
2017-05-30 |
2024-05-28 |
Bristol Myers Squibb Co |
LAG-3-pozitív tumorok kezelése
|
|
BR112019021847A2
(pt)
|
2017-05-30 |
2020-06-02 |
Bristol-Myers Squibb Company |
Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
|
|
US12259379B2
(en)
|
2017-06-30 |
2025-03-25 |
Osaka University |
Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood T cells as index
|
|
UA128472C2
(uk)
|
2017-08-25 |
2024-07-24 |
Файв Прайм Терапеутікс Інк. |
B7-h4 антитіла і методи їх використання
|
|
EP4576103A3
(en)
|
2017-10-10 |
2025-08-27 |
Gritstone bio, Inc. |
Neoantigen identification using hotspots
|
|
US12178787B2
(en)
|
2017-10-12 |
2024-12-31 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
|
EP3714275A4
(en)
|
2017-11-22 |
2021-10-27 |
Gritstone bio, Inc. |
REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
|
|
WO2019113072A1
(en)
*
|
2017-12-05 |
2019-06-13 |
Intendet Services, Inc. |
Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
|
|
BR112020016986A2
(pt)
|
2018-02-21 |
2021-03-02 |
Five Prime Therapeutics, Inc. |
formulações de anticorpo contra b7-h4
|
|
CA3091801A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
AU2019322487B2
(en)
|
2018-03-19 |
2024-04-18 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
EP4066851A1
(en)
|
2018-03-25 |
2022-10-05 |
SNIPR Biome ApS. |
Treating & preventing microbial infections
|
|
BR112020019251A2
(pt)
|
2018-03-27 |
2021-01-12 |
Board Of Regents, The University Of Texas System |
Compostos com atividade anti-tumor contra células de câncer com mutações de her2 exon 19
|
|
JP7474702B2
(ja)
|
2018-03-28 |
2024-04-25 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法
|
|
MX2020010913A
(es)
|
2018-04-17 |
2021-01-08 |
Celldex Therapeutics Inc |
Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
WO2020106621A1
(en)
|
2018-11-19 |
2020-05-28 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
CN113316455A
(zh)
|
2018-11-29 |
2021-08-27 |
得克萨斯大学体系董事会 |
用于离体扩增自然杀伤细胞的方法及其用途
|
|
WO2020136879A1
(ja)
*
|
2018-12-28 |
2020-07-02 |
国立大学法人大阪大学 |
悪性腫瘍を治療するための免疫療法剤の有用性の提示方法及び悪性腫瘍を治療するための免疫療法剤
|
|
CN120468425A
(zh)
*
|
2019-01-30 |
2025-08-12 |
国家医疗保健研究所 |
用于鉴定患有癌症的受试者是否将获得对免疫检查点抑制剂的应答的方法和组合物
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
AU2020268199B2
(en)
|
2019-05-09 |
2025-08-21 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
|
CN114096240A
(zh)
|
2019-05-17 |
2022-02-25 |
癌症预防制药股份有限公司 |
用于治疗家族性腺瘤性息肉病的方法
|
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
TWI895295B
(zh)
|
2019-11-12 |
2025-09-01 |
美商方得生醫療公司 |
偵測編碼新生抗原之融合基因之方法
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
US12251449B2
(en)
|
2019-12-19 |
2025-03-18 |
William Marsh Rice University |
Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
|
|
JP2023509516A
(ja)
|
2020-01-07 |
2023-03-08 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
|
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
US20230114276A1
(en)
*
|
2020-03-06 |
2023-04-13 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Modulating anti-tumor immunity
|
|
CN115803084A
(zh)
|
2020-05-21 |
2023-03-14 |
得克萨斯大学体系董事会 |
具有vgll1特异性的t细胞受体和其用途
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
AU2021377699A1
(en)
|
2020-11-13 |
2023-06-15 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
AU2021388155A1
(en)
|
2020-11-25 |
2023-06-15 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
|
CA3205538A1
(en)
|
2021-01-19 |
2022-07-28 |
Han XIAO |
Bone-specific delivery of polypeptides
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
|
KR20240116708A
(ko)
|
2021-10-05 |
2024-07-30 |
사이토비아 테라퓨틱스, 엘엘씨. |
자연 살해 세포 및 이의 사용 방법
|
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
|
US20240409934A1
(en)
|
2021-10-25 |
2024-12-12 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
WO2023172514A1
(en)
|
2022-03-07 |
2023-09-14 |
Catamaran Bio, Inc. |
Engineered immune cell therapeutics targeted to her2 and methods of use thereof
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
IL316628A
(en)
|
2022-05-12 |
2024-12-01 |
Genmab As |
Binding agents capable of binding to CD27 in combination therapy
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|